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Abstract
Background: Insight is impaired in a majority of people with schizophrenia. Impaired insight is associated with
poorer outcomes of the disorder. Based on existing literature, we developed a model that explains which
processes may possibly play a role in impaired insight. This model was the starting point of the development of
REFLEX: a brief psychosocial intervention to improve insight in schizophrenia. REFLEX is a 12-sessions group
training, consisting of three modules of four sessions each. Modules in this intervention are: “coping with stigma”,
“you and your personal narrative”, and “you in the present”.
Methods/Design: REFLEX is currently evaluated in a multicenter randomized controlled trial. Eight mental health
institutions in the Netherlands participate in this evaluation. Patients are randomly assigned to either REFLEX or an
active control condition, existing of cognitive remediation exercises in a group. In a subgroup of patients, fMRI
scans are made before and after training in order to assess potential haemodynamic changes associated with the
effects of the training.
Discussion: REFLEX is one of the few interventions aiming specifically to improving insight in schizophrenia and
has potential value for improving insight. Targeting insight in schizophrenia is a complex task, that comes with
several methodological issues. These issues are addressed in the discussion of this paper.
Trial registration: Current Controlled Trials: ISRCTN50247539
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1. Background
The percentage of persons with schizophrenia who have
only limited insight into their illness is large, ranging
from 50-80% [1]. Insight is considered a combination of
a number of dimensions, that can fluctuate indepen-
dently of each other, including awareness of mental ill-
ness, relabeling of symptoms and awareness of need for
treatment [2]. Insight in schizophrenia is usually mea-
sured with a semi-structured interview, such as the SAI-
E [3], SUM-D [4], and item G12 of the PANSS-inter-
view [5], or self-rating questionnaires, such as the Beck
Cognitive Insight Scale [6], and the Psychosis Insight
Scale [7].
Poor insight has a negative impact on relevant out-
comes of the disorder [see for a review: [8]]. Poor treat-
ment compliance in patients mediates this relationship,
but there is also a direct association between insight and
outcome [9]. Limited insight has been associated with
more positive and negative symptoms [10], more relapse
and rehospitalizations [9], lower GAF-scores [11], and
better observer quality of life and social functioning [9].
However, good insight may also have unfavorable conse-
quences. Several studies have shown better insight to be
associated with more depressive symptoms [8]. The
exact nature of this relationship remains unclear [8,10].
The relationship between depression and insight is
thought to be mediated by internalized stigma: insight is
only associated with depression in patients who hold
stigmatizing beliefs about mental illness [12,13].
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Given the negative impact of limited insight on the
outcome of schizophrenia, insight is a logical target for
treatment. However, treatment options to enhance
insight are limited. Psycho-education does not necessa-
rily lead to better insight [14], neither does psycho-
dynamic psychotherapy [15]. Turkington et al. [16]
developed a treatment program that combines psycho-
education on medication with cognitive behavioral ther-
apy. Treatment adherence improved and patients were
better able to label their symptoms as psychotic both
immediately and one year after treatment. In others stu-
dies, no clear effects of cognitive behavioural therapy on
insight was found [17].
Kemp et al. [18] demonstrated that therapy adherence
and insight in symptoms improved after a brief inter-
vention based on the principles of motivational inter-
viewing. Others studied the same intervention, with
inconsistent results [19,20]. Two smaller studies showed
that when patients are confronted with video images of
themselves during a psychotic episode, their insight
improves [21,22]. In sum, although there are several
interventions aiming to enhance insight in schizophre-
nia, there is still a need for improvement.
Three types of models have been put forward to
explain this variance: the clinical model, the neuropsy-
chological model, and the psychological denial model
[23]. The clinical model suggests that poor insight is a
primary symptom of schizophrenia, analogous to delu-
sions and hallucinations. The neuropsychological model
argues that specific cognitive impairments are responsi-
ble for poor insight in schizophrenia [24,25]. Finally, the
psychological denial model explains poor insight as the
outcome of a coping strategy that is used to reduce the
distress associated with a diagnosis of schizophrenia
[26].There is limited support for the clinical model,
partly because of the lack of testable hypotheses. Litera-
ture does provide evidence for the neuropsychological
model and some preliminary support for the psychologi-
cal denial model [23], but none of these models alone
can account for the variance in insight.
Recent evidence [27] suggests that one aspect of cog-
nitive functioning may have been overlooked in insight
literature: social cognition. Social cognition refers to
“the mental operations underlying social interactions,
like the ability and capacity to perceive the intentions
and dispositions of others” [28]. In particular, the ability
to take perspective has been linked to insight[[29]; Pij-
nenborg, Spikman, Jeronimus and Aleman: Insight in
schizophrenia: the role of affective perspective taking
and empathy, submitted]. In other words: the ability to
infer mental states was associated with the tendency to
take another person’s perspective on oneself.
Based on these findings, we propose a model that
integrates elements from previous models and combines
them with recent findings on the role of social cognition
in insight [30]. According to this model (see Figure 1)
self-reflection moderates the relationship between the
prerequisites for insight on the one hand and insight on
the other. Self-reflection is considered a meta-cognitive
process that concerns the ability to reflect upon
thoughts and feelings [31]. Self-reflection is thought to
be impaired in schizophrenia; patients demonstrate diffi-
culties in generating personal narratives that link the
past with the present [32,33]. The model explains why
schizophrenia patients with poor insight erroneously
hold on to their pre-morbid self-image. Because these
patients do not adjust their self-images to changing cir-
cumstances, they implicitly assume that functioning and
future perspective are still the same as before their ill-
ness started. In other words: they make too few self-cor-
rections. A number of processes are thought to hamper
self-reflection in schizophrenia. First of all, poor insight
is associated with a lack of mental flexibility [25].We
propose that this relationship is mediated by self-reflec-
tion. A lack of mental flexibility will hamper the capa-
city to consider alternatives and make complex
inferences about oneself, which will inevitably result in
poor insight. Second, recent evidence shows that insight
in schizophrenia is associated with Theory of Mind
(ToM) and in particular the ability to take the perspec-
tive of others [34]. ToM refers to the ability to interpret
mental states of others, or the notion that mental repre-
sentations of the world do not necessarily reflect reality,
and can be different from one’s own [35]. According to
David [36], insight requires a capacity for self-reflection
and the ability to make self-evaluations. David quotes
18th century Scottish poet Robert Burns to illustrate that
the ability to ‘see oursels as others see us’ helps people in
making these evaluations about themselves. ‘Seeing
yourself through the eyes of others’ is a process that
overlaps with ToM, and in particular with the ability to
take the perspective of another person to evaluate your
own mental state. Indeed, schizophrenia patients are
found to recognize symptoms of mental illness in others,
but not in themselves [37]. However, a direct link
between insight and perspective-taking is thought to be
unlikely, as perspective-taking is not primarily intended
for self-evaluation [29]. In line with our model, Langdon
and Ward suggest self-reflection as a mediator in this
relationship. Indeed, Dimaggio et al. [38] described an
association between self-reflection and ToM. The last
precondition of insight in our model is stigma-sensitiv-
ity. Schizophrenia is associated with a heavy stigma.
There is evidence that some patients cope with the
threat that stigma poses to their self-esteem by denying
the illness [39,40].
Psychological defensiveness in psychosis is associated
with unawareness of having a mental disorder,
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unawareness of the effects of antipsychotic medication
and inability to attribute symptoms to a mental disorder
[26]. Cooke et al. [23] also reported an association
between better insight and lower self-esteem (but not
depression) and implied the influence of a psychological
mechanism that preserves self-esteem. In addition, una-
wareness of having a mental disorder is associated with
more denial of common personal failings [41]. Appar-
ently, some patients are reluctant, at an unconscious
level, to reflect upon themselves in the light of a severe
mental illness. In line with our model, patients with les-
ser abilities for self-reflection and patients who endorse
stereotypes about mental illness tell more impoverished
stories about themselves [12]. The model is in line with
Beck’s [6] concept of cognitive insight. Cognitive insight
is seen as a prerequisite of insight and encompasses the
capacity of patients with psychosis to distance them-
selves from their psychotic experiences, reflect on them,
and respond to corrective feedback. This concept clearly
overlaps with the concepts self-reflection, non-social
cognition and perspective-taking in our model.
We used this model to develop an intervention to
improve insight in schizophrenia. This group-based
intervention, from now on referred to as REFLEX, con-
sist of three modules of four sessions each. The central
theme of the first module is dealing with stigma. The
second and third module aim to stimulate self-reflec-
tion through structured exercises. These exercises
facilitate mental flexibility and perspective-taking. In
the second module, patients reflect upon differences
between their past and present circumstances and
attributes. In the third module, patients are required to
reflect upon their thoughts and feelings in the present.
The present paper presents the design of a randomized
controlled multicenter trial aiming to evaluate the effi-
cacy of REFLEX.
Research aims
Main aim of the study is to evaluate the efficacy of
REFLEX. Primary outcome measures in this evaluation
are the preconditions of insight as specified by our
model, while insight is the secondary outcome measure
of our trial. Effects of REFLEX on quality of life, self-
esteem and mood will be examined as well.
An additional aim of the trial is to examine whether
participation in REFLEX will lead to haemodynamic
changes, blood oxygenation levels as measured by func-
tional Magnetic Resonance imaging (fMRI), during per-
spective-taking and self-reflection.
2. Methods/Design
The study is funded in part by a European Young Inves-
tigator (EURYI) Award from the European Science
Foundation to AA. Other contributions (in terms of per-
sonnel involved) are from the mental health centers
involved. The research has been approved by the medi-
cal ethical board of University Medical Center Gronin-
gen, Groningen (number: NL2714604209; date: 13-10-
2009), and is conducted in accordance with the princi-
ples of the Declaration of Helsinki.
2.1 Design
The study is a randomized controlled trial, including an
intervention group and an active control group. The
experimental group consists of patients who participate





Figure 1 A model of impaired insight in schizophrenia.
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participate in an adapted form of cognitive remediation
for an equal amount of time.
2.2 Participants/Setting
A total of 128 patients will be included in the trial.
Inclusion criteria for the study are:
• Impaired insight, defined as a) a score of <9 on the
Psychosis Inventory (Birchwood et al., 1994) and b)
impaired insight rated by a clinician (defined as one
or more non-affirmative answers on the following
three questions: “Is the patient aware that his/her
functioning is suboptimal due to mental illness?
Does the patient recognize the symptoms of his con-
dition? Does the patient acknowledge the need for
treatment?”). In case of an inconsistency between a)
and b) a PANSS interview [5] is administered.
Patients with a score > 3 on item G12 pass the
threshold for inclusion.
• A diagnosis of schizophrenia according to DSM-
IV-TR criteria
• > eighteen years old
• Being able to give informed consent
Exclusion criteria are:
• Receiving CBT at the moment of inclusion
• The presence of a florid psychosis
• A co-morbid neurological disorder
• No competence of the Dutch language
A subsample of 40 patients will also participate in the
fMRI part of the study. These patients will have to be
eligible for fMRI. Additional exclusion criteria for the
fMRI part of the study are: pregnancy or possibility
thereof, metal implants in the body, and claustrophobia.
Patients will be recruited in eight mental health insti-
tutions in the Netherlands.
2.3 Sample size calculation
A previous study on a treatment to improve insight in
schizophrenia [42] observed a mean effect size of 0.51
(standardized mean difference). We used this effect size
for our power analysis. Sample size was computed using
the program developed by David Schoenfeld, Ph.D (Har-
vard School of Public Health) http://hedwig.mgh.har-
vard.edu/biostatistics/software.Using the estimated effect
size of 0.51, this yielded a total number of 128 patients,
with a power of 0.80.
2.4 Materials
2.4.1 REFLEX treatment protocol
REFLEX encompasses three modules of four one-hour
group sessions each. Module I “Coping with Stigma”
focuses on coping with stigmatizing beliefs. The impact
of stigmatizing beliefs is discussed and stigmatizing
beliefs are disputed and replaced with functional reality-
based beliefs about the self. Patients learn that a diagno-
sis is just a label, saying little about them.
The goal of this module is twofold: first, we presume
that denial to cope with the threat that mental illness
poses on the self-esteem will be less necessary when
the idea of having a mental illness is perceived as less
threatening. Following this train of thought, challen-
ging stigmatizing beliefs will ultimately contribute to
better insight. Second, with the inclusion of the stigma
module we want to prevent an increase of depression
to co-occur with increasing insight, as literature has
shown that stigma mediates the relationship between
insight and mood. In the module “you and your perso-
nal narrative” self-reflection is the central theme. Sub-
jects reconstruct their personal narrative, reflect on
important changes in their lives and their personal
strengths and weaknesses. By offering very structured
exercises with clear instructions, REFLEX compensates
for cognitive impairments that are thought to hamper
self-reflection in schizophrenia. In this module, sub-
jects start practising perspective-taking. Subjects are
instructed to ask themselves on a regular basis what
other people would think about their thoughts and to
check this with an important other. In the third mod-
ule, called “you in the present”, reflection about
ongoing thoughts and feelings is stimulated. Between
sessions, subjects monitor their thoughts and feelings
in their daily life by experience-sampling [43]. In
response to a random signal (beeping of a watch) pro-
vided six times a day, patients write down the answer
to a fixed number of short questions that stimulate
self-reflection in a diary. Examples of these questions
are: “what was I thinking about before the alarm went
off?” and “what would other people think about this
thought?”. During group sessions, the content of these
dairies is discussed. In addition, group exercises and
movie vignettes are used to practice perspective-taking
during treatment sessions.
2.4.2 Control condition
The control condition of our study consists of twelve
group sessions of standardized ‘drill and practice’ exer-
cises to cognitive functioning. Exercises were adopted
from Cognitive Remediation Training protocol [44]
that aims to improve cognitive functioning by combin-
ing errorless learning (by using tasks varying from
extremely easy to easy), immediate feedback, and tar-
geted reinforcement to enhance flexibility, working
memory, and planning. Only exercises targeting cogni-
tive functions that are not associated with insight were
selected, trainers did not provide feedback on subject’s
performance.
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2.4.3 Screening
Insight: The Psychosis Insight Scale (PI) [7]: an eight item
self-report questionnaire, consisting of three subscales:
awareness of illness; relabeling symptoms to illness, and
need for treatment. Total scores range from 0 to 12.
2.4.3 Assessment
2.4.3.1 Behavioral measures
Primary outcome measures (preconditions of insight)
As REFLEX aims to improve insight via improving its
preconditions, preconditions of insight according to our
model are the trials primary outcome measures.
Internalized stigma The Internalized Stigma of Mental
Illness Scale (ISMI;[45] is a self-rating questionnaire
designed to measure the subjective experience of stigma,
with subscales measuring Alienation, Stereotype Endor-
sement, Perceived Discrimination, Social Withdrawal
and Stigma Resistance. The ISMI was developed in col-
laboration with people with mental illnesses and con-
tains 29 Likert items.
Self-reflection and mental flexibility The Beck Cogni-
tive Insight Scale (BCIS; [6]) is a self-rating question-
naire developed to evaluate patients’ self-reflectiveness
and idiosyncratic self-certainty (the ability to consider
other possibilities than one’s own opinion). The scale
consists of 15-items, divided into two subscales: a 9-
item self-reflectiveness subscale and a 6-item self-cer-
tainty subscale. Total scores are obtained by subtracting
the score of the self-certainty subscale from the score
on the self-reflectiveness subscale.
Self-reflection The Self-Reflection and Insight Scale [46]
is a self-rating questionnaire consisting of the factors
‘Need for self-reflection’, ‘Engagement in Self-reflection’
and ‘Insight’. The scale consists of 20 Likert-scale items.
Perspective-taking The Theory of Mind subscale of the
Davos Assessment of Cognitieve Biases Schaal
(DACOBS) [Van der Gaag, Schütz, Ten Napel, Landa,
Delaspaul, Bak & Tsacher, The development of the Daa-
vos Assessment of Cognitive Biases Scale, in prepara-
tion] was used to assess perspective-taking. The
DACOBS is 42-item Likert self-rating scale that mea-
sures cognitive biases and safety behavior in psychosis.
It consists of seven subscales: jumping to conclusions,
dogmatic bias, selective attention for threat, self-as-tar-
get bias, Theory of Mind problems and safety behavior.
The Theory of Mind subscale encompasses six items, e.
g.: If I hear other people laugh, I think they are laughing
at me.
Secondary outcome measures (Insight)
Insight The Schedule for Assessment of Insight-Expanded
(SAI-E) [3] an 11-item semi-structured interview to
assess insight, based on David’s three dimensions of
insight. The SAI-E takes both the opinion of the inter-
viewer and the caretakers into account.
Insight Item G12 of the Positive and Negative Symptom
Scale (PANSS) [5]. Item G12 is one of the thirty items
of the PANSS and exist of a seven-point scale, ranging
from 1 (very good insight) to seven (no insight). Item
G12 of the PANSS is often used to assess insight in psy-
chosis and is highly correlated with other insight mea-
sures, such as the SAI, SAI-E and ITAQ [47].
Insight The Beck Cognitive Insight Scale (BCIS, [6]) is a
15-item self-report questionnaire to evaluate patients’
reflectiveness and their overconfidence in their interpre-
tations of their experiences. The 15 items yield a 9-item
self-reflectiveness subscale and a 6-item self-certainty
subscale.
Other outcome measures (Correlates of insight)
Depression The Quick Inventory of Depressive Sympto-
matology Self-Report (QIDS-SR) is a 16-item self-report
questionnaire that rates depressive symptoms according
to the DSM-IV in the week before assessment [48].
Self-esteem The Self-Esteem Rating Scale-Short Form is
a self-report questionnaire that measures self-esteem. It
encompasses statements that are linked to social con-
tacts, achievement and competency [49] and is validated
for people with schizophrenia.
Symptoms The Positive and Negative Symptom Scale
(PANSS; [5] was used to measure psychopathology.
Quality of Life The Self-rating Manchester Short Assess-
ment of Quality of Life (MANSA; [50] is a 16 Likert-
scale item measure derived from the Lancashire Quality
of Life Profile [51]. The MANSA consists of four objec-
tive questions and twelve subjective questions. The sub-
jective items assess satisfaction with life as a whole, job,
financial situation, number and quality of friendships,
leisure activities, accommodation, personal safety, people
that the individual lives with (or living alone), sex life,
relationship with family, physical health and mental
health.
2.4.3.2 fMRI
Self-reflection During the self-reflection task subjects
view 180 different short sentences (white letters on a
black screen), subdivided into three main conditions (60
sentences per condition). Patients are presented state-
ments, which refer to themselves ("self-condition”), to a
significant other ("other-condition”), and to semantic
knowledge ("baseline condition”). The self-condition is
subdivided into four conditions (15 sentences per condi-
tion): a ‘negative’ mental condition (for example sen-
tences as ‘I am insensible’, ‘I forget important things’), a
‘positive’ mental condition (’I am intelligent’, ‘I am hon-
est’.), a negative physical condition (’I am often ill’, ‘I am
fat’), and a positive physical condition (’I am strong’, ‘I
am healthy).
The other-condition also includes ‘negative’ and ‘posi-
tive’ sentences concerning mental qualities or physical
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qualities. Examples of sentences included in the ‘seman-
tic knowledge condition’ are ‘Milk is red’, ‘Dogs run fas-
ter than snails’ and ‘Birds eat cats’. The amount of true/
false items in this condition is balanced.
Perspective-taking The perspective-taking paradigm is
adapted from a paradigm developed by Hooker and col-
leagues [52]. The paradigm consists of three conditions:
a control condition, emotion recognition, and emotion
inference. To familiarize patients with the task five prac-
tice items for each condition are presented before
patients enter the scanner. Each condition consists of 25
images of social scenarios. During the control condition,
patients simply have to count the number of people in
the scene. For the Emotion Recognition task, patients
are required to identify the emotion of a character in
the scene that was indicated with a fixation cross.
Answers are presented in a four-option multiple choice
format. In the Emotion Inference task, patients are
asked what the character indicated by the fixation cross
would feel if she/he had full knowledge about what is
happening in the scene. Half of the characters in this
condition holds a false belief. Answers are once more
presented in a four-option multiple choice format. In
both the Emotion Recognition and the Emotion Infer-
ence task emotional valence is balanced within the emo-
tion recognition and emotion interference condition.
Two parallel versions of the paradigm were developed,
to prevent practice effects and for pre- and post treat-
ment testing
2.5 Procedure
Patients who fulfill the inclusion criteria, will be invited
to participate in the study. If a patient is willing to parti-
cipate, study procedures will be explained in detail and
after a period of two weeks written informed consent is
obtained. Subsequently, diagnosis is verified by the Mini
Plus, a semi-structured interview to assess DSM IV
pathology [53]. Thereafter, patients are randomly allo-
cated to REFLEX or control condition. Randomization
procedures start when the required number of patients
per center (ranging from 17-19) are included, or when
the first patients was included more than six weeks ago
while >10 people are included.
Randomization is centrally coordinated by the Trial
Coordination Center of the University Medical Hospital
Groningen. The project coordinator gives the subject a
unique code and these codes are entered for each
patient into a computerized systematic program by an
independent researcher. Results of the randomization
process are passed to the project coordinator in sealed
envelopes and distributed to the on-site therapists. Sub-
sequent subjects are randomized in blocks of two or
four, to ensure that the number of patients will be
balanced over conditions. Assessment takes place before
(T1), directly after (T2) and six months after the train-
ing (T3). Assessors are not aware of the condition (con-
trol or treatment) the subject is in. During the entire
trial patients receive treatment as usual, with the excep-
tion of cognitive behavioral therapy.
All fMRI scans will be made in the Neuroimaging
Center of the UMCG in Groningen, right before (T1)
and directly after (T2) treatment. For geographical rea-
sons, recruitment for the fMRI study is limited to the
institutions located in the North of the Netherlands:
GGZ Drenthe, Assen; UMCG and Lentis, Groningen,
and GGZ Friesland, Leeuwarden. Patients who partici-
pate in the fMRI study will be randomized separately.
3. Statistical analysis
3.1 Behavioral data
Analysis will be performed according to the intention to
treat principle. Differences in scores on each of the
dependent variables will be examined for T1-T3. The
significance of possible differences will be tested with
logistic multilevel modeling [54] with the condition
(REFLEX or Control) and treatment phase (T1-T3) as
levels. A model will be built for each of the dependent
variables. Dummy variables will be created for each level
and the statistical significance of the regression effects
will be tested using the approximate t-test. The dummy
variables and their interaction are entered as fixed
effects in the model. As random effects, the between-
individual and within-individual variance were esti-
mated. All models will be built using the program
MlwiN.
3.2 fMRI
Scans will be acquired using a 3T Phillips Intera Quaser
(Best, The Netherlands) equipped with a synergy SENSE
eight-channel head coil. Functional images are acquired
using a T2*-weighted echo-planar sequence with 37
interleaved axial slices oriented approximately 10-20° to
the ac-pc transverse plane, a thickness of 3.5 mm and
no slice gap to cover the entire cortex (TR = 2 s, TE =
35 ms, flip angle = 70 degrees, FOV = 224 mm, 64 × 64
matrix of 3.5 × 3.5 × 3.5 voxels). In addition, two T1-
weighted 3-D fast field echo (FFE) anatomical images
(voxel size, 1 × 1 × 1 mm) containing 160 slices (TR =
25 ms; TE = 4.6 ms; slice-thickness = 1 mm; 256 × 256
matrix; FOV 26 cm) will be acquired parallel to the
bicommissural plane. Data will be preprocessed using
the Statistical Parametric Mapping software package
(SPM8, Wellcome Department of Cognitive Neurology,
London, UK: http://www.fil.ion.ucl.ac.uk) in the follow-
ing order: functional images will be corrected for slice
timing, realigned to the first volume of the first run to
correct for shifts in head position and coregistered to
the anatomy. Coregistrations were controlled manually
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for each subject to ensure correct coregistration. Func-
tional images were spatially normalized based on the
basis of the MNI (Montreal Neurological Institute) T1
template and then spatially smoothed with a 10 mm
full-width half-maximum (FWHM) isotropic Gaussian
Kernel. Preprocessed data will be analyzed to calculate
the main effects of Condition and the two-way interac-
tion of Condition x Phase.
4. Discussion
REFLEX may have a potential for improving insight in
patients with schizophrenia. Our design offers the
opportunity not only to examine the results of REFLEX
at a behavioral level, but takes underlying changes in
brain activation into account as well. With the study, we
hope to contribute to the existing knowledge of what
mechanisms are underlying changes in insight in schizo-
phrenia. Improving insight in schizophrenia is a challen-
ging task that needs careful consideration. During the
development of the intervention, some clinicians
addressed that patients might become more depressed if
their insight would improve. Although the evidence for
the development of depression is not conclusive [23],
we paid special attention to this issue. As was explained
in the introduction of this paper, there is evidence that
this risk concerns patients with internalized stigma. By
including a module that aims to reduce internalized
stigma, we feel we have minimized this potential risk.
Second, by definition, patients with impaired insight
often do not feel they need treatment and will not spon-
taneously enroll in a therapy trial to improve their
insight. Therefore, a common language needed to be
developed. We cannot simply give patients a phone call,
tell them that they are mentally ill and not fully aware
of this and expect them to participate in our study.
Instead, patients will be explained that being under
treatment in a mental health institution brings about a
lot of changes in their daily lives. REFLEX may help
them to recognize these changes and gain more control
over their lives. In a previous and unpublished pilot
study we found that explaining the aim of REFLEX in
comparable phrasing was acceptable to most patients
and made them consider participation. Third, a metho-
dological problem that is associated with insight is that
most assessment instruments are based upon the tradi-
tional medical model: patients have to use the same ter-
minology as their psychiatrists to be considered
insightful. This approach ignores the insight some
patients demonstrate, when they are able to describe the
problems they experience in daily life and to attribute
these problems to a mental illness. If they do not use
the term “psychosis” or “schizophrenia” to describe their
mental health, their insight is rated as impaired by most
of the current instruments. However, this may be just a
discussion about labels and not about actual insight. We
hope to have solved this problem by including scales
that measure the preconditions of insight, such as the
BCIS that measures cognitive insight, to traditional
insights scales. The BCIS does not measure agreement
insight in and medical way, but takes into account how
patients perceive their own thoughts and feelings.
Finally, care as usual for people with schizophrenia in
the Netherlands is extensive. Psycho-education, Liber-
man training modules (social skills), and CBT are acces-
sible for most patients. Because of this extensive care, it
is very hard to obtain treatment effects over and above
the effect of care that is already provided. However, sev-
eral studies have shown that specific interventions can
make a significant contribution to relevant outcome
measures [55,56]. Through the unique focus in REFLEX
on the improvement of self-reflectivity and perspective
taking abilities and by that improving insight we expect
to make a significant contribution to the well-being of
people with schizophrenia.
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